ABSTRACT
We conducted the largest GWAS meta-analysis for obstructive sleep apnoea (OSA; Ncases= 230,657; Ncontrols= 1,377,442) using European ancestry genetic data from five countries. We identified 147 independent loci associated with OSA, and estimated SNP-based heritability at 16%. We report six independent loci in a separate African population meta-analysis (Ncases= 46,834; Ncontrols= 149,192). We observed spatially resolved gene enrichment involving GABAergic and glutamate pathways, synaptic transmission, and cytoskeletal remodelling. OSA-derived polygenic risk scores showed predictive ability for clinician ascertained OSA status, Fitbit-derived sleep features, and self-reported sleep traits in participants of diverse ancestral backgrounds. We identified putative causal relationships with ADHD, depression, multisite chronic pain, body mass index, and schizophrenia, among others. Our findings demonstrate a robust genetic component underlying OSA risk, independent of body mass index, implicating distinct neurobiological pathways related to synaptic function and corticothalamic feedback loops.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project used data from the UK-Biobank under application number 25331. We want to acknowledge Mass General Brigham Biobank for providing samples, genomic data, and health information. We thank the National Institutes of Health's All of Us Research Program for making the participant level data available for our study. We also thank the participants in the All of US Research Program for making this study possible. We want to acknowledge the participants and investigators of the FinnGen study. This research was made possible using the data/biospecimens collected by the Canadian Longitudinal Study on Aging (CLSA). Funding for the Canadian Longitudinal Study on Aging (CLSA) is provided by the Government of Canada through the Canadian Institutes of Health Research (CIHR) under grant reference: LSA 94473 and the Canada Foundation for Innovation, as well as the following provinces, Newfoundland, Nova Scotia, Quebec, Ontario, Manitoba, Alberta, and British Columbia. This research has been conducted using the CLSA dataset [Baseline Comprehensive Dataset version 4.0, Follow-up 1 Comprehensive Dataset version 1.0, Genetic data version 3.0], under Application Number 190225. The CLSA is led by Drs. Parminder Raina, Christina Wolfson and Susan Kirkland. The time and commitment of the participants to the CLSA study platform is gratefully acknowledged, without whom this research would not be possible. The opinions expressed in this manuscript are the author's own and do not reflect the views of the Canadian Longitudinal Study on Aging or any affiliated institution. Data collection for the Australian Genetics of Depression Study was possible thanks to funding from the Australian National Health & Medical Research Council (NHMRC) to N.G.M. (GNT1086683). ZC is supported by funding from the National Institute of Mental Health (R01MH129356 awarded to ACE). VFO expresses thanks for the PhD Scholarship support from the Global Parkinson's Genetic Program (GP2). BU is supported by the Higher Degree Research (HDR) Tuition Fee Scholarship (TFS) from Queensland University of Technology (QUT) and a QIMR Computational Neurogenomics Laboratory scholarship. FC is supported by scholarships from the University of Queensland and the QIMR Computational Neurogenomics Laboratory. MER thanks the support from the Rebecca L. Cooper Medical Research Foundation (F20231230). We thank all the investigators of the Guangzhou Biobank Cohort Study (GBCS) for their generous contribution of genetic and longitudinal data that made this work possible. SM is supported by a research fellowship from the Australian NHMRC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our study is based on previously published GWAS summary data and publicly available data for which appropriate site-specific institutional review boards and ethical reviews at local institutions were approved for the use of these data. All participants included in the present study provided written informed consent, and the investigators in the participating studies obtained approval from their institutional review board or equivalent organization. For some cohorts, we conducted the analyses using anonymised individual-level data: AGBD, AGDS, UK Biobank CLSA and AoU. For FinnGen and MVP, we only used publicly available summary data. For the Mass General Brigham Biobank, we also utilised summary data generated as part of a previously published paper (doi: 10.1093/sleep/zsac308).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
